---
title: Thorough QT Study of Nelfinavir
nct_id: NCT00312182
overall_status: COMPLETED
phase: PHASE4
sponsor: Pfizer
study_type: INTERVENTIONAL
primary_condition: Healthy Volunteers
countries: United States, Belgium, Singapore
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00312182.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00312182"
ct_last_update_post_date: 2009-04-10
last_seen_at: "2026-05-12T06:56:22.561Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Thorough QT Study of Nelfinavir

**Official Title:** Evaluation Of The Effect Of Nelfinavir On QT Intervals At Steady-State After Twice-Daily Administration Of Nelfinavir Tablets To Healthy Volunteers

**NCT ID:** [NCT00312182](https://clinicaltrials.gov/study/NCT00312182)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 68
- **Lead Sponsor:** Pfizer
- **Conditions:** Healthy Volunteers
- **Start Date:** 2006-03
- **Completion Date:** 2006-06
- **CT.gov Last Update:** 2009-04-10

## Brief Summary

To assess if nelfinavir has any clinically meaninful effect on cardiac function, namely ECG evaluation

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy male and female subjects between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of approximately 18 to 30 kg/m2.

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
```

## Interventions

- **Nelfinavir** (DRUG)

## Primary Outcomes

- **ECG evaluation**

## Secondary Outcomes

- **Pharmacokinetics**

## Locations (4)

- Pfizer Investigational Site, New Haven, Connecticut, United States
- Pfizer Investigational Site, Ann Arbor, Michigan, United States
- Pfizer Investigational Site, Brussels, Belgium
- Pfizer Investigational Site, Singapore, Singapore

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.pfizer investigational site|new haven|connecticut|united states` — added _(2026-05-12)_
- `locations.pfizer investigational site|ann arbor|michigan|united states` — added _(2026-05-12)_
- `locations.pfizer investigational site|brussels||belgium` — added _(2026-05-12)_
- `locations.pfizer investigational site|singapore||singapore` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00312182.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00312182*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*